Abstract

Each of the three clinical trials of this proposal will be supported by the cores. The main function of the clinical cell processing core (Core B) will be to generate and provide DC preparations that will be used in each of the clinical trials of this program. Additionally, the cell processing core will be responsible for the further development and scale-up of the DC preparations and their functional validation. An important function of this core will be to explore methods to improve DC preparation and RNA transfection conditions using serum free conditions. Interactions with biotechnology and pharmaceutical companies will allow for development of devices and methods of cell processing that can be expanded for large scale clinical trials.
The specific aims of Core B are:
Aim 1 Provide clinical cell processing of RNA transfected DC for clinical trials in Project 1 and 3.
Aim 2 Utilize clinical grade reagents in large, sale, develop clinical strategies of generating DC from PBMC isolated following cytokine mobilization with G-CSF, GM-CSF and Flt3 ligand.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA078673-02
Application #
6315284
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2000-05-19
Project End
2001-03-31
Budget Start
Budget End
Support Year
2
Fiscal Year
2000
Total Cost
Indirect Cost

  Institution

Name
Duke University
Department
Type
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705

  Publications

Morse, Michael A; Niedzwiecki, Donna; Marshall, John L et al. (2013) A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann Surg 258:879-86
Aldhamen, Y A; Seregin, S S; Kousa, Y A et al. (2013) Improved cytotoxic T-lymphocyte immune responses to a tumor antigen by vaccines co-expressing the SLAM-associated adaptor EAT-2. Cancer Gene Ther 20:564-75
Osada, Takuya; Morse, Michael A; Hobeika, Amy et al. (2012) Novel recombinant alphaviral and adenoviral vectors for cancer immunotherapy. Semin Oncol 39:305-10
Seregin, Sergey S; Aldhamen, Yasser A; Rastall, David P W et al. (2012) Adenovirus-based vaccination against Clostridium difficile toxin A allows for rapid humoral immunity and complete protection from toxin A lethal challenge in mice. Vaccine 30:1492-501
Ren, Xiu-Rong; Wei, Junping; Lei, Gangjun et al. (2012) Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells. Breast Cancer Res 14:R89
Seregin, Sergey S; Amalfitano, Andrea (2011) Gene therapy for lysosomal storage diseases: progress, challenges and future prospects. Curr Pharm Des 17:2558-74
Hartman, Zachary C; Wei, Junping; Glass, Oliver K et al. (2011) Increasing vaccine potency through exosome antigen targeting. Vaccine 29:9361-7
Schuldt, Nathaniel J; Aldhamen, Yasser A; Appledorn, Daniel M et al. (2011) Vaccine platforms combining circumsporozoite protein and potent immune modulators, rEA or EAT-2, paradoxically result in opposing immune responses. PLoS One 6:e24147
Seregin, Sergey S; Aldhamen, Yasser A; Appledorn, Daniel M et al. (2011) TRIF is a critical negative regulator of TLR agonist mediated activation of dendritic cells in vivo. PLoS One 6:e22064
Osada, Takuya; Chen, Minyong; Yang, Xiao Yi et al. (2011) Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. Cancer Res 71:4172-82

Showing the most recent 10 out of 49 publications